Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ImCheck Therapeutics logo — Bringing a novel class of Butyrophilin-targeted checkpoint m...

ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

Founded 2015 France France 57 employees Grant Total: $193.11M Biopharma, Biotechnology +3

General Information

Company Name ImCheck Therapeutics
Founded Year 2015
Location France France +1
Employees 57
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Grant
Social

Get notified when ImCheck Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ImCheck Therapeutics

ImCheck Therapeutics, with the slogan "Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic," is focused on designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. Their lead clinical-stage program ICT01 has demonstrated a mechanism of action to simultaneously modulate innate and adaptive immunity. This "first-in-class" activating antibody may produce superior clinical results compared to first-generation immune checkpoint inhibitors. Additionally, when used in combination, it can potentially overcome resistance to this group of agents. ImCheck is also evaluating antagonist antibodies as potential treatments for a range of autoimmune diseases. Founded in 2015 and headquartered in France, ImCheck benefits from the co-founder of the Marseille Immunopole cluster, Prof. Daniel Olive, a worldwide leader in γδ T cells and butyrophilins research. The company also has an expert management team and the commitment of leading US and European investors. The last investment was a €20.18M grant investment received on 29 August 2024 from France 2030. ImCheck Therapeutics operates in the Biopharma, Biotechnology, Health Care, Health and Wellness, and Life Sciences industries. With its innovative approach and strong support, ImCheck Therapeutics is poised to make a significant impact in the field of immunotherapy.

Taxonomy: immunotherapy, oncology, antibody therapeutics, cancer treatment, immune checkpoint inhibitors, autoimmune diseases, immunomodulators, biopharmaceuticals, drug development, precision medicine

Services & Products

development of immunotherapeutic antibodies
immune system modulation research
clinical research in AML patients

Target Customers

patients with cancer patients with infectious diseases patients with autoimmune diseases

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 29 Aug 2024
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		13 Jun 2022
Series B •••••• 1 •••• •••• 15 Sep 2020
Series B •••••• 10
Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		04 Dec 2019
Grant •••••• 1
Investor
01 Aug 2019

View All 7 Funding Rounds

Latest News

View All
Germany’s Earlybird raises €173m healthtech fund as it looks to tap 'unprecedented' biopharma opport... — Sifted
Germany’s Earlybird raises €173m healthtech fund as it looks to tap 'unprecedented' biopharma opportunity
Sifted Feb 14, 2024
Healthcare sector attracts increased interest: Earlybird Health's new €173M fund — Tech
Healthcare sector attracts increased interest: Earlybird Health's new €173M fund
Tech Feb 14, 2024
22 techbio soonicorns ready to cross the $1bn threshold — Sifted
22 techbio soonicorns ready to cross the $1bn threshold
Sifted Feb 22, 2024
Kurma Partners raises €140 million first close of new €250 million Biofund IV — Eu-startups
Kurma Partners raises €140 million first close of new €250 million Biofund IV
Eu-startups Oct 03, 2024
Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics — Tech
Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics
Tech Oct 22, 2025
Earlybird Health promotes two new partners as firm deepens biotech and analytics focus — Tech
Earlybird Health promotes two new partners as firm deepens biotech and analytics focus
Tech Oct 29, 2025

ImCheck Therapeutics Alternatives & Competitors

ImCheck Therapeutics vs
Innate Pharma
Innate Pharma France

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improvi...

Post Ipo Secondary
196 employees
Biopharma, Biotechnology
Compare ImCheck Therapeutics vs Innate Pharma
ImCheck Therapeutics vs
BioInvent International AB
BioInvent International AB Sweden

BioInvent is translating cancer antibody biology into innovative immuno-oncology therapies.

IPO
139 employees
Biotechnology, Health Care
Compare ImCheck Therapeutics vs BioInvent International AB
ImCheck Therapeutics vs
Surface Oncology Inc.
Surface Oncology Inc. United States

#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021

Post Ipo Equity
14 employees
Biotechnology, Health Care
Compare ImCheck Therapeutics vs Surface Oncology Inc.

FAQ About ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic
ImCheck Therapeutics was founded in 2015.
ImCheck Therapeutics is headquartered in France.
ImCheck Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care, Health and Wellness, Life Sciences.
ImCheck Therapeutics has approximately 57 employees.
ImCheck Therapeutics has completed 7 funding rounds, raising a total of $193.11M. The latest funding stage is Grant.
ImCheck Therapeutics offers: development of immunotherapeutic antibodies, immune system modulation research, clinical research in AML patients.
Top alternatives and competitors to ImCheck Therapeutics include Innate Pharma, BioInvent International AB, Surface Oncology Inc., Alderaan Biotechnology, Tridek-One. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImCheck Therapeutics and Innate Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ImCheck Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy